2cureX Yönetim

Yönetim kriter kontrolleri 2/4

2cureX CEO'su Ole Thastrup, Jan2006 tarihinde atandı, in görev süresi 18.83 yıldır. in toplam yıllık tazminatı SEK 300.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 50% maaş ve 50% ikramiyelerden oluşmaktadır. şirketin hisselerinin 23.8% ine doğrudan sahiptir ve bu hisseler SEK 1.94M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 2 yıldır.

Anahtar bilgiler

Ole Thastrup

İcra Kurulu Başkanı

SEK 300.0k

Toplam tazminat

CEO maaş yüzdesi	50.0%
CEO görev süresi	18.8yrs
CEO sahipliği	23.8%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ole Thastrup'un ücretlendirmesi 2cureX'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-SEK 26m
Mar 31 2024	n/a	n/a	-SEK 30m
Dec 31 2023	SEK 300k	SEK 150k	-SEK 33m
Sep 30 2023	n/a	n/a	-SEK 33m
Jun 30 2023	n/a	n/a	-SEK 31m
Mar 31 2023	n/a	n/a	-SEK 29m
Dec 31 2022	SEK 150k	n/a	-SEK 30m
Sep 30 2022	n/a	n/a	-SEK 29m
Jun 30 2022	n/a	n/a	-SEK 26m
Mar 31 2022	n/a	n/a	-SEK 25m
Dec 31 2021	SEK 150k	n/a	-SEK 19m
Sep 30 2021	n/a	n/a	-SEK 15m
Jun 30 2021	n/a	n/a	-SEK 10m
Mar 31 2021	n/a	n/a	-SEK 8m
Dec 31 2020	SEK 2m	SEK 2m	-SEK 7m
Sep 30 2020	n/a	n/a	-SEK 7m
Jun 30 2020	n/a	n/a	-SEK 8m
Mar 31 2020	n/a	n/a	-SEK 8m
Dec 31 2019	SEK 2m	SEK 2m	-SEK 8m
Sep 30 2019	n/a	n/a	-SEK 6m
Jun 30 2019	n/a	n/a	-SEK 6m
Mar 31 2019	n/a	n/a	-SEK 6m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 7m

Tazminat ve Piyasa: Ole 'nin toplam tazminatı ($USD 27.65K ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 239.32K ).

Tazminat ve Kazançlar: Ole şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Ole Thastrup (71 yo)

18.8yrs

Görev süresi

SEK 300,000

Tazminat

Mr. Ole Thastrup is CEO of 2cureX AB (publ) since June 2024 and serves as it's Vice Chairman of the Board since January 01, 2024 and served as the Chief Scientific Officer since January 2021 until January...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ole Thastrup	Co-Founder	18.8yrs	SEK 300.00k	23.8% SEK 1.9m
Grith Hagel	Co-Founder	no data	Veri yok	3.87% SEK 314.9k
Kenneth Johansen	Chief Financial Officer	3.8yrs	Veri yok	0.023% SEK 1.8k
Jacob Thastrup	Chief Technology Officer	less than a year	Veri yok	0.062% SEK 5.0k
Manuel Fernandez	Director Quality & Regulatory Affairs	no data	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: 2CUREX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ole Thastrup	Co-Founder	18.8yrs	SEK 300.00k	23.8% SEK 1.9m
Grith Hagel	Co-Founder	less than a year	Veri yok	3.87% SEK 314.9k
John Marshall	Member of Clinical Advisory Board	3.3yrs	Veri yok	Veri yok
Tonni Bülow-Nielsen	Chairman of the Board	less than a year	Veri yok	Veri yok
Jesus Garcia-Foncillas	Member of Clinical Advisory Board	3.3yrs	Veri yok	Veri yok
Andrew Beggs	Member of Clinical Advisory Board	3yrs	Veri yok	Veri yok
Nathaniel Hutley	Director	less than a year	Veri yok	Veri yok
Dan Honeywell	Director	less than a year	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 2CUREX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

2cureX Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

2cureX AB (publ) Approves the Election of New Board Members

2cureX AB (publ) Announces CEO Changes

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

2cureX AB (publ), Annual General Meeting, May 23, 2024

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

Recent updates

2cureX AB (publ) Approves the Election of New Board Members

First half 2024 earnings released: kr0.54 loss per share (vs kr0.89 loss in 1H 2023)

2cureX AB (publ) to Report Fiscal Year 2024 Final Results on Apr 24, 2025

2cureX AB (publ) Announces CEO Changes

2cureX AB (publ) to Report Q4, 2024 Results on Feb 20, 2025

No independent directors

2curex AB (publ) Elects Grith Hagel as a New Board Member

Full year 2023 earnings released: kr1.75 loss per share (vs kr1.69 loss in FY 2022)

2cureX AB (publ), Annual General Meeting, May 23, 2024

2cureX AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

2cureX AB (publ) Receives Ethical Approval for HIPEC Clinical Trial

Third quarter 2023 earnings released: kr0.58 loss per share (vs kr0.47 loss in 3Q 2022)

2Curex AB (Publ) Appoints Tonni Bülow-Nielsen as Board Member and Chairman

New minor risk - Share price stability

2curex Launches Its First Two IndiTreat® Products Ce-Marked Under the New Ivd Regulation

New major risk - Financial position

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.45 loss in 1Q 2022)

Chief Executive Officer recently bought kr136k worth of stock

Chief Executive Officer recently bought kr136k worth of stock

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

Full year 2022 earnings released: kr1.69 loss per share (vs kr1.15 loss in FY 2021)

2cureX AB (publ) Appoints Michel Klimkeit to Board of Director

2cureX AB (publ) to Report Q4, 2023 Results on Feb 22, 2024

Third quarter 2022 earnings released: kr0.47 loss per share (vs kr0.31 loss in 3Q 2021)

High number of new and inexperienced directors

2cureX AB (publ), Annual General Meeting, May 25, 2023

2cureX Announces Board Change

Chief Executive Officer recently bought kr84k worth of stock

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

2cureX AB (publ) Presents Inditreat® Clinical Results At the Society for Functional Precision Medicine

High number of new and inexperienced directors

Manuel Fernández Joins 2cureX as Director of Quality Assurance and Regulatory Affairs

2cureX AB (publ) Announces Management Changes

2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans

2cureX Launches IndiTreat mCRC Start Test to Guide First Line Treatment

We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

2cureX Announces New Development of the IndiTreat Technology Allows Prediction of Response to Anti-Angiogenic Drugs in Colorectal Cancer

High number of new and inexperienced directors

We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow

2Curex AB (Publ) Clinical Partner, University Hospital Vejle, Presents Positive Results of Thnditreat®-Guided Clinicaical Trial in Third Line Metastatic Colorectal Cancer At the Asco 2021 Annual Meeting

Co-Founder exercised options to buy kr7.6m worth of stock.

2cureX AB (publ) Announces Clinical Trial of Inditreat®-Guided Treatment of Metastatic Colorectal Cancer

2cureX AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return

2cureX AB's IndiTreat® Selected to Prestigious Multinational Ovarian Cancer Project

New 90-day high: kr22.60

Chief Financial Officer has left the company

2cureX Appoints Kenneth Graabek Johansen as New CFO, Effective 1 February 2021

2cureX Announces Last Patient Treated in the World's First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day high: kr17.65

2cureX Announces Management Changes

2cureX AB (publ), Annual General Meeting, May 27, 2021

How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?

New 90-day low: kr16.25

2cureX Announces Last Patient Successfully Enrolled in the Worlds First Interventional Trial with 3D Microtumors as Guide for Choice of Cancer Treatment

New 90-day low: kr17.30

2cureX launches world's first CE-marked microtumor test service

New 90-day high - kr22.50

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi